news, journals and articles from all over the world.
In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumor DNA damage response.
Read moreIn a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).
Read moreAtlantic Health System Cancer Care physicians are co-authors of five original studies presented at this year’s AACR Annual Meeting, held virtually April 10-15 and May 17-21. The AACR meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers.
Read moreThe National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and cedazuridine (100 mg).
Read more
In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).
Read more
The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.
Read more
According to a new study led by Yale Cancer Center and Department of Neurology researchers, a simple blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat advanced melanoma, a deadly form of skin cancer. The findings were published today in the Journal of Experimental Medicine.
Read more
Yale School of Medicine announces a gift to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center. The Chênevert Family Brain Tumor Center will be a leading center in Neuro-Oncology research worldwide, bringing ground-breaking solutions and hope to patients with brain tumors.
Read more
In a new study led by Yale Cancer Center, researchers demonstrate sex hormones and insulin growth factors are associated with recurrence risk of endometrial cancer.
Read more
Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as an Associate Professor of Medicine (Medical Oncology).
Read more
A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen PET imaging, PSMA PET, a novel imaging technique that recently was approved by the U.S. Food and Drug Administration.
Read moreThe clinical research conducted through the Center will investigate how to use light to improve people’s lives by stabilizing their circadian rhythms, the natural internal clock that regulates the body’s sleep-wake cycle. Researchers will study how light, either from daylight or electric indoor light, affects circadian rhythms in various populations, from the very young to the very old, including patients with COVID-19, cancer, Alzheimer’s disease, depression, and other illnesses. The goal is to help abate symptoms and improve their sleep, mental health, and cognition.
Read more
In a new study led by Yale Cancer Center, researchers have discovered a novel metabolic gatekeeper mechanism for leukemia. This mechanism depends on a molecule called PON2, which could lead to a new treatment for the disease. The findings were published online today in the Proceedings of the National Academy of Sciences.
Read more
Dana-Farber Cancer Institute is having a virtual discussion for cancer patients and survivors about the Covid-19 vaccine on January 27, 2020 at 5 pm.
Read more
Rachel Adams Greenup, MD, MPH, FACS, has been appointed as Associate Professor of Surgery (Oncology) and Section Chief of Breast Surgery for the Department of Surgery at Yale School of Medicine. In her new role, Dr. Greenup will provide breast surgical oncology leadership across the Smilow Cancer Hospital Network and Care Centers.
Read more
The colons of African-Americans and people of European descent age differently, new research reveals, helping explain racial disparities in colorectal cancer – the cancer that killed beloved “Black Panther” star Chadwick Boseman.
Read moreA phase 2 clinical trial providing personalized treatments based on the genetic profile of metastatic tumors in gastroesophageal cancers has found that using customized treatment approaches, and adapting them over time as tumors become resistant, led to higher rates of survival compared to historical controls.
Read more
While decades of research have resulted in substantial improvements in surviving cancer, a key challenge remains in identifying new drugs that improve outcomes for patients. In APL Bioengineering, researchers suggest a major hurdle is the paucity of models for cancer research that accurately represent patient tumors. They provide a perspective on strategies using models from individual patients and where the field needs to go in terms of research in animal systems and in culture systems.
Read moreBen Ferguson joins the UNM Comprehensive Cancer Center as surgical oncologist. It was the complexity of cancer care that drew him to the specialty and the resources of a comprehensive cancer center that drew him to UNM.
Read more
Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.
Read more
Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.
Read more
Following an extensive national search, Stephanie Halene, MD, PhD, has been appointed Chief of Hematology at Yale Cancer Center, Smilow Cancer Hospital and the Yale School of Medicine Department of Internal Medicine.
Read more
Henry Ford Cancer Institute and United Outstanding Physicians (UOP), a physician organization comprising nearly 1,000 independent private practice physicians across Southeast Michigan, have come together to enhance cancer care and make navigating the cancer journey easier for their patients.
Read more
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.
Read more
A phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center found IMGN632, a novel CD123-targeting antibody-drug conjugate, was tolerable and resulted in a 29% overall response rate in patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm.
Read more
Anita Kinney, professor at the Rutgers School of Public Health and associate director for Population Science and Community Outreach at Rutgers Cancer Institute of New Jersey, is one of ten recipients across the nation of an American Cancer Society and Pfizer community grant of $399,892 to support investigation into reducing racial health disparities in cancer care through precision oncology and immunotherapy.
Read moreSUMMARY Researchers have developed the first report card on biosimilars for three blockbuster cancer drugs marketed by Genentech/Roche: Rituxan, Avastin
Read more
In a new study by Yale Cancer Center, researchers found substantial regional variation in use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies.
Read moreThe Huntsman Cancer Institute, College of Pharmacy and PIVOT Center have partnered to establish the University of Utah Therapeutic Accelerator Hub. The new Accelerator will provide resources and expertise to researchers to support the process of translating research discoveries into innovative clinical applications.
Read moreA team including researchers from the NYU Tandon School of Engineering and NYU Langone Health demonstrated an in vitro organotypic “leukemia-on-a-chip” model to emulate in vivo leukemia bone marrow pathology and study chemiresistance.
Read more
In a new study by Yale Cancer Center, scientists have identified the short endosomal protein interferon-inducible transmembrane protein 3 or IFITM3 as a central amplifier to supercharge activation of immune cells.
Read moreFour MSK researchers out of 15 winners nationwide were named recipients of the prestigious award. They will each receive a grant of up to $600,000 per year for seven years to support their research in cancer.
Read moreNeuro-oncologist and renowned physician-scientist Ingo Mellinghoff will lead MSK’s distinguished Department of Neurology after previously serving as Acting Co-Chair.
Read more
Atlantic Health System has announced the opening of Morristown Medical Center’s new state-of-the-art, patient-centered Infusion Center located in the Carol G. Simon Cancer Center. The first of three phases of expansion of New Jersey’s pre-eminent cancer center, the new unit was funded in large part by donations made by community members in support of the Foundation for Morristown Medical Center’s Growing Forward Campaign.
Read more
Michaela A. Dinan, PhD, has been appointed Co-Leader of the Cancer Prevention and Control Research Program at Yale Cancer Center.
Read moreMemorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
Read moreA pay-for performance program that offers enhanced reimbursement to oncology practices for prescribing high-quality, evidence-based cancer drugs increased use of these drugs without significantly changing total spending on care, Penn Medicine researchers report in a new study published online in the Journal of Clinical Oncology.
Read moreComputational biologist Thomas Norman, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will receive $1.5 million in direct costs upfront in the first year of a five-year award.
Read more
The tools will help doctors and patients make better-informed treatment decisions, enhance the care of brain metastases, and enable hospitals to improve the coordination and effectiveness of their interdisciplinary treatment programs.
Read more
Loved or hated, the humble oat could be the new superfood for cancer patients as international research shows a diet rich in fibre could significantly reduce radiation-induced gut inflammation.
Read more
According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.
Read moreSeattle Cancer Care Alliance (SCCA), committed to delivering patient-centered, high-quality cancer care as the only NCCN-designated cancer center in Washington State, announced that members of its clinical nursing staff will participate in 10 poster presentations during the 2020 Oncology Nursing Society (ONS) Bridge Virtual Conference. The meeting is being held September 8, 10, 15 and 17, 2020.
Read more
Hackensack Meridian Jersey Shore University Medical Center recently launched a Cardio-Oncology Program providing cancer patients and survivors access to cardiology and oncology specialists and advanced imaging services. L. Steven Zukerman, M.D., FACC, serves as medical director of the program, designed to minimize the impact of cancer treatments on patients’ hearts and provide continuing cardiac care to cancer survivors.
Read more
In laboratory studies, Johns Hopkins Kimmel Cancer Center and Johns Hopkins University researchers observed a key step in how cancer cells may spread from a primary tumor to a distant site within the body, a process known as metastasis.
Read moreIn a breakthrough study, researchers at Children’s Hospital of Philadelphia (CHOP) have shown that an enhanced treatment developed in their lab leads to long-term remissions in 80% to 100% of mice with drug-resistant or high-risk solid tumors. The research, which could soon lead to clinical trials, is described in Cancer Research, a journal of the American Association for Cancer Research.
Read more
Researchers at UC San Diego School of Medicine and Moores Cancer Center report that an investigational drug candidate called tipifarnib showed promise in treating key recurring mutation in head and neck cancers.
Read moreAn international team of researchers has developed a non-invasive blood test that can detect whether an individual has one of five common types of cancers, four years before the condition can be diagnosed with current methods. The test detects stomach, esophageal, colorectal, lung and liver cancer.
Called PanSeer, the test detected cancer in 91% of samples from individuals who had been asymptomatic when the samples were collected and were only diagnosed with cancer one to four years later.
Mercy Medical Center is the first institution in the United States to study the role of CRS/HIPEC for newly diagnosed with ovarian, fallopian tube, or primary peritoneal cancers. Literature exists involving CRS/HIPEC in the role of recurrent disease and in the neoadjuvant setting; however, there is no published data on the role as a primary treatment option in the United States.
Read more
The discovery of the oncogene responsible for glioblastoma could be the brain tumor’s Achilles’ heel, one researcher says.
Read more
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.
Read more